We are live on ! Find out more
INBX

Inhibrx, Inc. Common Stock

Delisted

INBX was delisted on the 29th of May, 2024.

61 hedge funds and large institutions have $539M invested in Inhibrx, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 28 increasing their positions, 8 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 8

75% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 8

65% more capital invested

Capital invested by funds: $326M → $539M (+$213M)

11% more funds holding

Funds holding: 5561 (+6)

Holders
61
Holders Change
+6
Holders Change %
+10.91%
% of All Funds
1.06%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
14
Increased
28
Reduced
8
Closed
8
Calls
Puts
Net Calls
Net Calls Change

INBX Hedge Fund Activity: Q2 2021 in Review

61 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Inhibrx, Inc. Common Stock (INBX) for Q2 2021, worth a combined $539M — up 65% from $326M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new INBX positions and 8 closed out — a net gain of 6 holders — while 28 added to existing stakes and 8 trimmed.

The largest buyer was Perceptive Advisors, opening a new position worth an estimated $18.9M. The largest seller was Soleus Capital Management, cutting an estimated $3.3M.

  • 61 institutional investors held Inhibrx, Inc. Common Stock (INBX) as of Q2 2021, up from 55 in Q1 2021.
  • Funds reported $539M of Inhibrx, Inc. Common Stock stock for Q2 2021, up 65% quarter-over-quarter.
  • 14 funds opened new Inhibrx, Inc. Common Stock positions in Q2 2021 and 8 closed out, a net change of +6 holders.
  • The largest Inhibrx, Inc. Common Stock buyer in Q2 2021 was Perceptive Advisors, an estimated $18.9M added.
  • The largest Inhibrx, Inc. Common Stock seller in Q2 2021 was Soleus Capital Management, an estimated $3.3M sold.

Based on aggregated 13F filings for Q2 2021.